Lobbying Information
Subject Matters
- Economic Development
- Health
- Industry
- Intellectual Property
- International Trade
- Science and Technology
- Taxation and Finance
Subject Matter Details
Policies or Program
- Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.
- Engagement with the Advisory Committee on the Implementation of National Pharmacare and its Secretariat on issues related to access to medicines and rare disorder and orphan drug policies
- Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
- Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
- Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
- Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
Policies or Program, Regulation
- Proposed amendments to the Patented Medicines Regulations pre-published in the Canada Gazette Part 1 on December 2, 2017, specifically, proposals to change the basket of comparator countries (Schedule), addition of economic factors as mandatory considerations in price excessiveness evaluations and requirements to report third party rebates and benefits.
- Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Senate of Canada
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
20 Bay Street
Suite 1520
Toronto, ON M5J 2N8
Canada
Telephone number:
647-790-1602
Web address:
www.vrtx.com
Client representative
Christina Cunningham, Director of Public Affairs - Canada
Parent Company Information
- Vertex Pharmaceuticals Incorporated
-
50 Northern Ave
Boston, MA 02210
United States of America
Coalition Members Information
Vertex Pharmaceuticals (Canada) Inc. is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Vertex Pharmaceuticals (Canada) Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Vertex Pharmaceuticals (Canada) Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
WILLIAM DEMPSTER
|
Public offices held
Business address:
150 Metcalfe Street
Suite 604
OTTAWA, ON K2P 1P1
Canada
Telephone number:
613-614-0283
Fax number:
613-249-3645
Consultant Firm and Address
Firm:
3Sixty Public Affairs Inc. / 3Sixty Public Affairs Inc.
Address:
150 Metcalfe Street
Suite 604
Ottawa, ON K2P 1P1
Canada
Telephone number:
613-800-8340
Fax number:
613-800-8343
